Membership is an attestation that we belong to the modern Latvian business community.
Dace Silava-Tomsone, Managing Partner, COBALT
EVENT: Precision Medicine Networking Forum (PMNET)
DATES: October, 13-14
VENUE: Riga Stradiņš University (Great Hall, Dzirciema street 16).
PARTNERS: Latvian Children’s Oncology Fund, Latvian Biomedical Research and Study Center, Riga Stradiņš University, Children’s Hospital Foundation and Children’s University Hospital of Latvia, Ministry of Economy of Latvia, Investment and Development Agency of Latvia and AmCham Latvia.
PMNET is event dedicated to precision medicine for oncological patients.
Applications of genomic technologies are disruptive, so the challenge for healthcare professionals, healthcare providers, as well as for researchers and in academia in general, is to learn how to best use precision medicine. All other stakeholders will need to ensure that their own knowledge continues to evolve, and this will require a greater emphasis on continual professional training. For example, if politicians and healthcare organizers are to discharge their tasks responsibly, they will have to take the need to be informed about all the implications of their decisions seriously.
The event will take place over 2 days, it will be dynamic and multidisciplinary and comprised of 10 sessions with range of national and international experts in clinical oncology, molecular diagnostics, bioinformatics, research, healthcare, research management, and economics. International clinical experts will share their experience in several areas, for example paediatric oncology, cancer of unknown primary, the role of molecular tumour boards, stratification of patients for clinical trials, and the importance of collaboration. Many patients and professionals expect high benefits from precision medicine and have a positive attitude towards it. However, patients and professionals also perceive some risks like lack of evidence for efficacy of treatments, the availability of the necessary therapy, and patients’ limited knowledge that makes informed consent more difficult, can lead to misuse of data and ethical issues.
PMNET will focus on the following topics:
Key specialists of genetics, oncology, diagnostics, bioinformatics as well as clinicians, researchers and other stakeholders (industry, policy makers etc) from Baltic States as well as from abroad are expected. To attract the participants - apart from a high-level scientific program - onsite excursions, networking opportunities, access to key opinion leaders, excellence of the industry, symposiums are planned.
We joined AmCham as a community of shared values to expand our access to global competencies and to foster the quality of the health ecosystem.
Agrita Kiopa, Vice Rector for Science, Riga Stradins University